Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.69 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17973296 | 0.89 | SLC22A12 (0.55) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL10177198 | 0.85 | TSHR (0.53) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4736104 | 0.83 | SLC22A12 (0.69) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15544155 | 0.82 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4736105 | 0.82 | SLC22A12 (0.68) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4736083 | 0.82 | CYP1A2 (0.48) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11915750 | 0.82 | SLC22A12 (0.92) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL29353441 | 0.82 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL842962 | 0.82 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL2678389 | 0.81 | SLC22A12 (0.67) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | claimed |
| EP-2870142-B1 | MANUFACTURE OF 2- (5- BROMO-4- (4-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID | ARDEA BIOSCIENCES INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2870142-B1 | MANUFACTURE OF 2- (5- BROMO-4- (4-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID | ARDEA BIOSCIENCES INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160214947-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214947-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214947-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9296709-B2 | Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid | ARDEA BIOSCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296709-B2 | Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid | ARDEA BIOSCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8242154-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242154-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8173690-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173690-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010028190-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-20160214947-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | CYP1B1, ABAT, ALDH18A1 | SLC22A12 3336/4885CYP2C9 51/4885CYP2C19 72/4885 |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.